An Adaptive,Multicentre, Phase IIa, Multi-disease Trial Investigating the Safety & Activity of a Single Infusion of Selected Mesenchymal Stromal Cells in the Treatment of Patients With Primary Sclerosing Cholangitis & Autoimmune Hepatitis
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 30 Nov 2018
At a glance
- Drugs Orbcel-C (Primary)
- Indications Autoimmune hepatitis; Primary sclerosing cholangitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms MERLIN
- 26 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 1 Dec 2018.
- 31 Aug 2018 Biomarkers information updated
- 04 Jun 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.